OSE Immunotherapeutics Reports Positive TEDOVA Data
NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...
KEYTRUDA
Advertisement
Gilead Expands Oncology Portfolio With Tubulis Deal
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Mestag Therapeutics Doses First Patient in STARLYS Trial of MST-0312 for Solid Tumors
CAMBRIDGE, UK, May 19, 2026 Mestag Therapeutics announced the first patient has been dosed in the Phase 1 STARLYS...
BioInvent Reports Strong BI-1808 CTCL Responses at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced new Phase 2a clinical data demonstrating that its investigational...
Advertisements
Merck Unveils Major Oncology Advances at ASCO 2026
RAHWAY, N.J., May 12, 2026 Merck announced a major expansion of its oncology research portfolio ahead of the 2026...
Labcorp Enables KEYTRUDA Access with FDA Diagnostic
BURLINGTON, N.C., April 22, 2026 Labcorp announced the nationwide availability of the FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic,...
Merck Wins EU Approval for KEYTRUDA Combo in Ovarian Cancer
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
Merck Advances GU Cancer Care With New ASCO Data
RAHWAY, N.J., Feb. 12, 2026 — Merck & Co. announced the presentation of extensive new clinical data in bladder...
KEYTRUDA Plus Padcev Extends Survival in MIBC Trial
RAHWAY, N.J., Dec. 17, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 (EV-304)...
Advertisement
